The FDA has approved Allergan's once-daily prescription eye drop Lumigan as a first-line treatment for elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension.
The Lumigan first-line indication is in addition to the product's already established use as a second-line treatment, for which the FDA approved the drug in 2001.
Read the full
article here.
Filed under Eye Treatment, Glaucoma
Related?
Akorn Receives FDA Approval for Glaucoma TreatmentMarch 27th, 2006 Drug maker Akorn Inc. received Food and Drug Administration approval for its Glaucoma treatment.
Allergan CEO works to protect blockbuster Botox from new challenger amid tough economyMay 9th, 2009 Allergan CEO defends Botox from new challengerWASHINGTON — Barely a week after the Food and Drug Administration cleared the way for a second anti-wrinkle drug, the maker of Botox is defending its product, warning physicians about the risks of switching between the two drugs. Allergan has good reason to defend Botox: it accounts for nearly one-third of the company's sales.
Watson Pharma gets FDA approval for generic Toprol XL and says it will launch drug immediatelyAugust 3rd, 2009 Watson Pharma says FDA approved generic Toprol XLMORRISTOWN, N.J. — Watson Pharmaceuticals Inc.
Ranbaxy gets USFDA's permission to manufacture cardiovascular drugsMarch 12th, 2009 MUMBAI - Drug-maker Ranbaxy Laboratories has got approval from the US Federal Drug Administration to market and manufacture Ramipril, which is used in the treatment of cardiovascular diseases. The pharmaceuticals company has received final nod from US Food and Drug Administration (US FDA) for Ramipril capsules, it said in a filing to the Bombay Stock Exchange.
Teva Pharmaceutical, Antares Pharma get FDA approval for hormone use in needle-free deviceJune 29th, 2009 Teva, Antares get FDA OK for hormone in new deviceNEW YORK — Teva Pharmaceutical Industries Ltd. and Antares Pharma Inc.
Novartis AG gets US approval for 2-year osteoporosis therapy ReclastJune 1st, 2009 Novartis osteoporosis treatment approved in USBASEL, Switzerland — Pharmaceutical company Novartis AG said Monday it received U.S. approval for its Reclast drug as a biannual osteoporosis treatment.
GlaxoSmithKline: FDA requires more data to approve experimental drug for nausea, vomitingJune 23rd, 2009 FDA: More data needed on Glaxo nausea drugTRENTON, N.J. — The U.S.
FDA warns doctors of botulism risk when Botox is used for off-label treatment of muscle spasmsApril 30th, 2009 FDA warns of deaths with unapproved use of BotoxWASHINGTON — Health officials warned doctors and patients Thursday about potentially deadly risks of using the anti-wrinkle drug Botox and similar drugs for unapproved uses to treat certain types of muscle spasms. The Food and Drug Administration said Botox and two other injections have been linked to rare botulism symptoms, particularly when given to children to help relax uncontrollable muscle movements.
